Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Start Date
5/16/2025
Completion Date
6/1/2030
Summary
The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Tirbanibulin ointment 1%
non-ablative fractional laser
Conditions
Locations
Bruce Robinson, MD
New York, New York 10022
United States